Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer.

Khasnis MD, Halkidis K, Bhardwaj A, Root MJ.

PLoS Pathog. 2016 Dec 19;12(12):e1006098. doi: 10.1371/journal.ppat.1006098. eCollection 2016 Dec.

2.

Design and characterization of ebolavirus GP prehairpin intermediate mimics as drug targets.

Clinton TR, Weinstock MT, Jacobsen MT, Szabo-Fresnais N, Pandya MJ, Whitby FG, Herbert AS, Prugar LI, McKinnon R, Hill CP, Welch BD, Dye JM, Eckert DM, Kay MS.

Protein Sci. 2015 Apr;24(4):446-63. doi: 10.1002/pro.2578. Epub 2014 Oct 31.

3.

SAMHD1 restricts HIV-1 replication and regulates interferon production in mouse myeloid cells.

Zhang R, Bloch N, Nguyen LA, Kim B, Landau NR.

PLoS One. 2014 Feb 19;9(2):e89558. doi: 10.1371/journal.pone.0089558. eCollection 2014.

4.

Anti-HIV activity of human defensin 5 in primary CD4+ T cells under serum-deprived conditions is a consequence of defensin-mediated cytotoxicity.

Ding J, Tasker C, Valere K, Sihvonen T, Descalzi-Montoya DB, Lu W, Chang TL.

PLoS One. 2013 Sep 25;8(9):e76038. doi: 10.1371/journal.pone.0076038. eCollection 2013.

5.

Drug-induced reactivation of apoptosis abrogates HIV-1 infection.

Hanauske-Abel HM, Saxena D, Palumbo PE, Hanauske AR, Luchessi AD, Cambiaghi TD, Hoque M, Spino M, D'Alliessi Gandolfi D, Heller DS, Singh S, Park MH, Cracchiolo BM, Tricta F, Connelly J, Popowicz AM, Cone RA, Holland B, Pe'ery T, Mathews MB.

PLoS One. 2013 Sep 23;8(9):e74414. doi: 10.1371/journal.pone.0074414. eCollection 2013.

6.

Differential profiles of immune mediators and in vitro HIV infectivity between endocervical and vaginal secretions from women with Chlamydia trachomatis infection: a pilot study.

Sperling R, Kraus TA, Ding J, Veretennikova A, Lorde-Rollins E, Singh T, Lo Y, Quayle AJ, Chang TL.

J Reprod Immunol. 2013 Sep;99(1-2):80-7. doi: 10.1016/j.jri.2013.07.003. Epub 2013 Aug 8.

7.

5' Unlocked Nucleic Acid Modification Improves siRNA Targeting.

Snead NM, Escamilla-Powers JR, Rossi JJ, McCaffrey AP.

Mol Ther Nucleic Acids. 2013 Jul 2;2:e103. doi: 10.1038/mtna.2013.36.

8.

Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Donahue DA, Bastarache SM, Sloan RD, Wainberg MA.

J Virol. 2013 Sep;87(17):9620-32. doi: 10.1128/JVI.01165-13. Epub 2013 Jun 26.

9.

Virion stiffness regulates immature HIV-1 entry.

Pang HB, Hevroni L, Kol N, Eckert DM, Tsvitov M, Kay MS, Rousso I.

Retrovirology. 2013 Jan 10;10:4. doi: 10.1186/1742-4690-10-4.

10.

Construction and testing of orfA +/- FIV reporter viruses.

Fadel HJ, Saenz DT, Poeschla EM.

Viruses. 2012 Jan;4(1):184-99. doi: 10.3390/v4010184. Epub 2012 Jan 23.

11.

A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs.

Lassen KG, Hebbeler AM, Bhattacharyya D, Lobritz MA, Greene WC.

PLoS One. 2012;7(1):e30176. doi: 10.1371/journal.pone.0030176. Epub 2012 Jan 24.

12.

TLR2 activation enhances HIV nuclear import and infection through T cell activation-independent and -dependent pathways.

Ding J, Chang TL.

J Immunol. 2012 Feb 1;188(3):992-1001. doi: 10.4049/jimmunol.1102098. Epub 2011 Dec 30.

13.

HIV-1 replication and latency are regulated by translational control of cyclin T1.

Hoque M, Shamanna RA, Guan D, Pe'ery T, Mathews MB.

J Mol Biol. 2011 Jul 29;410(5):917-32. doi: 10.1016/j.jmb.2011.03.060.

14.

Vpx rescues HIV-1 transduction of dendritic cells from the antiviral state established by type 1 interferon.

Pertel T, Reinhard C, Luban J.

Retrovirology. 2011 Jun 22;8:49. doi: 10.1186/1742-4690-8-49.

15.

Human defensins 5 and 6 enhance HIV-1 infectivity through promoting HIV attachment.

Rapista A, Ding J, Benito B, Lo YT, Neiditch MB, Lu W, Chang TL.

Retrovirology. 2011 Jun 14;8:45. doi: 10.1186/1742-4690-8-45.

16.

Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication.

Benton T, Lynch K, Dubé B, Gettes DR, Tustin NB, Ping Lai J, Metzger DS, Blume J, Douglas SD, Evans DL.

Psychosom Med. 2010 Nov;72(9):925-32. doi: 10.1097/PSY.0b013e3181f883ce. Epub 2010 Oct 14.

17.

Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.

Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS, Conway JA, Wieczorek L, Brown B, Polonis V, West JT, Montefiori DC, Kappes JC, Ochsenbauer C.

Virology. 2010 Dec 5;408(1):1-13. doi: 10.1016/j.virol.2010.08.028. Epub 2010 Sep 21.

18.

A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.

Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG, Doms RW.

J Virol. 2010 Oct;84(20):10863-76. doi: 10.1128/JVI.01109-10. Epub 2010 Aug 11.

19.

Neisseria gonorrhoeae enhances HIV-1 infection of primary resting CD4+ T cells through TLR2 activation.

Ding J, Rapista A, Teleshova N, Mosoyan G, Jarvis GA, Klotman ME, Chang TL.

J Immunol. 2010 Mar 15;184(6):2814-24. doi: 10.4049/jimmunol.0902125. Epub 2010 Feb 10.

20.

Human peritoneal macrophages from ascitic fluid can be infected by a broad range of HIV-1 isolates.

Chang TL, Klepper A, Ding J, Garber J, Rapista A, Mosoian A, Hubner W, Gutierrez J, Walewski J, Abergel J, Schiano T, Branch A.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):292-302. doi: 10.1097/QAI.0b013e3181ca3401.

Supplemental Content

Support Center